Brief: Lantern Pharma To Advance EMA-Cleared Phase 1B/2 Trial Of Lp-184 (Zirdafulven) In Biomarker-Selected Advanced Bladder Cancer
28/07/2026 12:51
BRIEF-Lantern Pharma To Advance EMA-Cleared Phase 1B/2 Trial Of Lp-184 (Zirdafulven) In Biomarker-Selected Advanced Bladder Cancer July 28 (Reuters) - Lantern Pharma Inc LTRN.O:
LANTERN PHARMA TO ADVANCE EMA-CLEARED PHASE 1B/2 TRIAL OF LP-184 (ZIRDAFULVEN) IN BIOMARKER-SELECTED ADVANCED BLADDER CANCER
Source text: ID:nBw5C2gMfa
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview